Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC) “We are proud to join ELCC 2025, a premier conference focused directly on the ...
Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung ...
CHICAGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer ...
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract ...
MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract about the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback